Schmoeckel E, et al. - Because most ovarian carcinomas (OC) have a poor prognosis, especially the most common type of high-grade serous carcinoma, and target-based therapeutic strategies are not well established beyond PARP inhibitors, researchers assessed if other therapeutic targets might be of potential value and analyzed a large OC cohort (n=288) for numerous predictive factors. Data reported that PD-L1 expression ≥ 1% in 19.5% of the cases was the most frequent finding, which was associated in multivariate analysis with a significantly better overall survival. According to findings, high-grade serous carcinoma subsets exhibit expression of PD-L1 and amplification of HER2, so they may qualify for immune checkpoint inhibitor therapy or anti-HER2 therapy, respectively. Also, PD-L1 has a prognostic impact. ALK/EML4 fusion is not a putative therapeutic target in OC and is very rare.